⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ADAG News
Adagene Inc. American Depositary Shares
Adagene to Participate in Two Upcoming Investor Conferences
globenewswire.com
ADAG
Cancer Immunotherapy Research Report 2026: Market Forecasts 2025-2029 for Immuno-Oncology Therapeutics by Therapy, Cancer and Customer with Executive and Consultant Guides
globenewswire.com
ABBV
ADAG
ADAP
ACET
ALXO
AMBR
AMGN
RCUS
AZN
ATRC
BBLU
BIIB
BNTX
BOLT
BMY
CRBU
CLDX
CRVS
LLY
EVAX
GNSS
GILD
GLSI
IMUX
IMMX
IMNM
INCY
INDP
ISRL
IOBT
JNJ
MRK
MRNA
MBIO
NVS
NVX
PDSB
PFE
REGN
SNY
SNT
URGN
ZYME
ACROBiosystems Powers Innovation at bioSeedin's JPM Spotlight, Strategically Supporting Global Partnership Forging
prnewswire.com
PFE
ABBV
TSE
GSK
ADAG
IMUX
Adagene Provides Business Update and 2026 Objectives
globenewswire.com
ADAG
Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126)
globenewswire.com
ADAG
MRK
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
globenewswire.com
ADAG
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
globenewswire.com
ADAG